An observational study in Rabies, Rabies Human and Rabies Virus Infection, sponsored by The Methodist Hospital Research Institute. Terminated at 2 sites in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-13.
Sponsored by The Methodist Hospital Research Institute · Observational
This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (PEP) in the ED.
BACKGROUND: Rabies PEP consists of thorough wound cleansing, administration of HRIG 20 IU/kg body weight, and 4 to 5 doses of rabies vaccine. The safety of HRIG 300 IU/mL has been confirmed only for adult patients. Although the safety of HRIG 300 IU/mL in the pediatric population has not been fully established, there is no age limit on the FDA approved indication for HRIG 300 IU/mL, and it is routinely administered to pediatric patients as standard of care in the United States.
STUDY DESIGN: This observational, multicenter, prospective study will collect information on safety events that occur up to 30 days after standard of care administration of HRIG 300 IU/mL among pediatric patients (age ≤17 years) at up to 5 study sites in the United States. Safety data will be collected using surveys and chart review of the health record. All participants will receive HRIG 300 IU/mL per standard of care prior to joining this study. The day of HRIG 300 IU/mL administration will be defined as day 0. The study will conduct Survey 1 on day 2 and Survey 2 on day 10 to collect information on adverse events (AEs). Investigators will review the electronic health record on day 30 to collect additional information on AEs. If a serious adverse event is detected during Survey 1, Survey 2, or the 30-day chart review and is not previously documented as being resolved or stabilized the study will conduct Survey 3 on day 30.
114 studies on the registry are indexed under Rabies; 15 are open to participants now.
Browse Rabies studies →The Methodist Hospital Research Institute is the lead sponsor of 160 studies on the registry; 59 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 18 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Pediatric patients who received HRIG 300 IU/mL as part of routine medical care for rabies PEP during an ED visit in up to 5 study sites in the United States
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Inability to obtain consent
All participants in this single-cohort observational study will receive human rabies immune globulin 300 IU/mL at a dose of 20 IU/kg per standard of care.
Incidence of local and systemic adverse events (AEs) within 2 days of HRIG 300 IU/mL administration
Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration
Time frame: Within 2 days of HRIG 300 IU/mL administration
Cumulative incidence of all local and systemic AEs within 10 days of HRIG 300 IU/mL administration
Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration
Time frame: Within 10 days of HRIG 300 IU/mL administration
Cumulative incidence of all local and systemic AEs within 30 days of HRIG 300 IU/mL administration
Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration
Time frame: Within 30 days of HRIG 300 IU/mL administration
Cumulative incidence of all local and systemic serious adverse events (SAEs) within 30 days of HRIG 300 IU/mL administration
Proportion of patients with 1 or more SAE deemed as possibly/definitely related to HRIG 300 IU/mL administration. An AE is considered "serious" if any of the following outcomes occur: * Death * Life-threatening AE (life-threatening in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * In-patient hospitalization or prolongation of existing hospitalization * A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions * An important medical event (refers to events which may not be immediately life-threatening, or result in death, or hospitalization, but from medical and scientific judgment, may jeopardize the participant or/and may require medical or surgical intervention to prevent one of the other outcomes listed above).
Time frame: Within 30 days of HRIG 300 IU/mL administration
Type and severity of individual local and systemic AEs detected within 30 days of HRIG 300 IU/mL administration
Proportions of AEs that are local vs systemic and proportions of AEs that are mild, moderate, or severe among AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration
Time frame: Within 30 days of HRIG 300 IU/mL administration
Plan to share: No
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Methodist Hospital Research Institute →